

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#7

In Re the Application of:

BAR-OR et al.


Serial No.: 10/076,071

Filed: February 13, 2002

Atty. File No.: 4172-3-2

For: METAL-BINDING COMPOUNDS
AND USES THEREFOR

Commissioner of Patents
Washington, D.C. 20231



Group Art Unit: 1614

Examiner:

INFORMATION DISCLOSURE
STATEMENT

CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS
BEING DEPOSITED WITH THE UNITED STATES POSTAL
SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE
ADDRESSED TO COMMISSIONER OF PATENTS,
WASHINGTON, D.C., 20231 ON 6/14/02

SHERIDAN ROSS P.C.

BY: [Signature]

Dear Sir:

Pursuant to Applicants' duty of disclosure under 37 CFR § 1.56 and 37 CFR §§ 1.97-1.98, Applicants hereby submit the enclosed PTO Form 1449. Certain of the documents identified herein were of record in U.S. Patent Application Serial No. 09/678,202, and since the above-identified patent application is a continuation thereof, copies of such documents are not being submitted under 37 CFR § 1.98(d). Applicants do not admit that any of such documents, alone or in any combination, are considered to be material to patentability as defined in 37 CFR § 1.56(b). Moreover, the inclusion of these documents is not to be construed as an admission by Applicants that each such document is prior art as to the above-identified patent application.

Respectfully submitted,

SHERIDAN ROSS P.C.

By: [Signature]

Gary J. Connell
Registration No. 32,020
1560 Broadway, Suite 1200
Denver, Colorado 80202-5141
(303) 863-9700

Date: June 14, 2002

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	ATTY. DOCKET NO. 4172-3-2	SERIAL NO. 10/076,071
	APPLICANT BAR-OR et al.	
	FILING DATE February 13, 2002	GROUP ART 1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROP.
	1	6,084,093	7/4/00	Riley et al.	540	465	
	2	6,083,758	7/4/00	Imperiali et al.	436	73	
	3	6,022,879	2/8/00	Crow et al.	514	319	
	4	6,017,888	1/25/00	Pallenberg et al.	514	19	
	5	6,004,953	12/21/99	Volpin et al.	514	185	
	6	5,994,339	11/30/99	Crapo et al.	514	185	
	7	5,922,761	7/13/99	Lai	514	476	
	8	5,906,996	5/25/99	Murphy	514	674	
	9	5,888,522	3/30/99	Pickart	424	401	
	10	5,874,573	2/23/99	Winchell et al.	540	465	
	11	5,858,993	1/12/99	Pickart	514	60	
	12	5,807,535	9/15/98	Smith et al.	424	1.65	
	13	5,786,335	7/28/98	Cody et al.	514	17	
	14	5,785,948	7/28/98	Itaya et al.	424	1.69	
	15	5,780,594	7/14/98	Carter	530	363	
	16	5,776,892	7/7/98	Counts et al.	514	11	
	17	5,770,178	6/23/98	Itaya et al.	424	1.69	
	18	5,739,395	4/14/98	Bergeron, Jr.	562	565	
	19	5,710,172	1/20/98	Kukreja et al.	514	400	
	20	5,683,907	11/4/97	Johnson	436	518	
	21	5,670,645	9/23/97	Johnson	546	141	
	22	5,670,627	9/23/97	Johnson	530	388.9	
	23	5,663,301	9/2/97	Johnson	530	363	
	24	5,654,160	8/5/97	Johnson	435	7.9	
	25	5,650,134	7/22/97	Albert et al.	424	1.69	
	26	5,639,624	6/17/97	Wagner et al.	435	7.92	


EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	ATTY. DOCKET NO. 4172-3-2	SERIAL NO. 10/076,071
	APPLICANT BAR-OR et al.	
	FILING DATE February 13, 2002	GROUP ART 1614

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROP.
	27	5,637,578	6/10/97	Riley et al.	514	186	
	28	5,637,311	6/10/97	Pallenberg	424	434	
	29	5,631,172	5/20/97	Johnson	436	543	
	30	5,628,982	5/13/97	Lauffer et al.	424	9.363	
	31	5,624,900	4/29/97	Suda et al.	514	13	
	32	5,591,711	1/7/97	Koyama et al.	514	6	
	33	5,585,466	12/17/96	Carter	530	363	
	34	5,554,375	9/10/96	Pickart	424	401	
	35	5,550,183	8/27/96	Pickart	514	6	
	36	5,538,945	7/23/96	Pallenberg et al.	514	6	
	37	5,527,522	6/18/96	Lauffer et al.	424	9.362	
	38	5,503,987	4/2/96	Wagner et al.	435	7.94	
	39	5,476,939	12/19/95	Johnson	546	141	
	40	5,470,876	11/28/95	Proctor	514	492	
	41	5,455,229	10/3/95	Hahn et al.	514	18	
	42	5,422,096	6/6/95	Lauffer et al.	424	9.363	
	43	5,382,431	1/17/95	Pickart	424	401	
	44	5,380,747	1/10/95	Medford et al.	514	423	
	45	5,348,943	9/20/94	Pickart	514	18	
	46	5,290,519	3/1/94	Bar-Or et al.	522	61	
	47	5,252,559	10/12/93	Kronholm et al.	514	18	
	48	5,227,307	7/13/93	Bar-Or et al.	436	63	
	49	5,214,032	5/25/93	Pickart	514	16	
	50	5,177,061	1/5/93	Pickart	514	18	
	51	5,164,367	11/17/92	Pickart	514	6	
	52	5,145,838	9/8/92	Pickart	514	18	
	53	5,135,913	8/4/92	Pickart	514	16	

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 4172-3-2	SERIAL NO. 10/076,071
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANT BAR-OR et al.	
		FILING DATE February 13, 2002	GROUP ART 1614




*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROP.
	54	5,120,831	6/9/92	Pickart	530	331	
	55	5,118,665	6/2/92	Pickart	514	6	
	56	5,104,865	4/14/92	Hider et al.	514	188	
	57	5,101,041	3/31/92	Troutner et al.	548	518	
	58	5,087,696	2/11/92	Parker et al.	540	465	
	59	5,059,588	10/22/91	Pickart	514	12	
	60	5,023,237	6/11/91	Pickart	514	18	
	61	4,912,118	3/27/90	Hider et al.	514	332	
	62	4,877,770	10/31/89	Pickart	514	18	
	63	4,810,693	3/7/89	Pickart	514	18	
	64	4,767,753	8/30/88	Pickart	514	18	
	65	4,760,051	7/26/88	Pickart	514	6	
	66	4,746,649	5/24/88	Raddatz et al.	514	18	
	67	4,684,624	8/4/87	Hosobuchi et al.	514	15	
	68	4,665,054	5/12/87	Pickart	514	18	
	69	4,591,648	5/27/86	Jones et al.	548	344	
	70	4,461,724	7/24/84	Konishi	260	112.5	
	71	4,025,499	5/24/77	Thomas	260	112.5	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
							YES	NO
	72	WO 00/20840	4/2000	PCT				
	73	WO 00/20454	4/2000	PCT				
	74	WO 99/45907	9/1999	PCT				
	75	WO 99/39706	8/1999	PCT				

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	ATTY. DOCKET NO. 4172-3-2	SERIAL NO. 10/076,071
	APPLICANT BAR-OR et al.	
	FILING DATE February 13, 2002	GROUP ART 1614



	76	WO 98/54138	12/1998	PCT				
	77	EP 0613560 B1	10/1998	EPO				
	78	WO 98/40071	9/1998	PCT				
	79	WO 97/49409	12/1997	PCT				
	80	WO 97/44313	11/1997	PCT				
	81	719790	12/1995	EPO				
	82	WO 94/26295	11/1994	PCT				
	83	WO 93/23425	11/1993	PCT				
	84	WO 93/10459	5/1993	PCT				
	85	WO 91/17760	11/1991	PCT				
	86	327263	1/1989	EPO				
	87	JP 62116565	5/1987	Japan				
	88	WO 00/21941	4/20/00	PCT				

OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)

✓	89	"Angiogenesis Inhibitors," found at http://www.cancerprotocol.com/angiogenesis_inhbitiors.html , January 28, 2002, 1 page
✓	90	"Metal Heads," from New Scientist, 26/8/00, found at http://purdeyenvironment.com/Full%20New%20scientist0001.htm , 6 pages
	91	"Metal-Binding Groups of Proteins: A. Evidence for Specific Donor Atoms," Chapter IV, pp. 61-99
✓	92	"The Role of Copper in the Angiogenesis Process," found at http://www.cancerprotocol.com/role_of_copper.html , January 28, 2002, 2 pages
	93	"Toxicity and Physicochemical Properties of Metal: Coordination and Chelation," Ch. 4, pp. 115-122
	94	Adman, <i>Advances in Protein Chemistry</i> , 42:145-197 (1991)
	95	Afans'ev, <i>Superoxide Ion: Chemistry and Biological Implications</i> , Vol. I, pp. 26, 51, 147, 168-196, 248-266 (CRC Press, Boca Raton, FL) (1989)
	96	Aitken, <i>Mol. Biotech.</i> , 12:241-253 (1999)
	97	Ames et al., <i>Proc. Natl. Acad. Sci. USA</i> , 90:7915-7922 (1993)
	98	Atanasiu et al., <i>Mol. Cell. Biochem.</i> , 189:127-135 (1998)
	99	Atwood et al., <i>J. Biol. Chem.</i> , 273(21):12817-12826 (1998)

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	


FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 4172-3-2	SERIAL NO. 10/076,071
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANT BAR-OR et al.	
		FILING DATE February 13, 2002	GROUP ART 1614



100	Aust, <i>Bibl. Nutr. Dieta</i> , Basel, Karger, No. 43, pp. 266-277 (1989)
101	Bal et al., <i>Chem. Res. Toxicol.</i> , 10(8):906-914 (1997)
102	Bal et al., <i>Chem. Res. Toxicol.</i> , 10:915-921 (1997)
103	Bar-Or et al., <i>Biochem. Biophys. Res. Commun.</i> , 284:856-862 (2001)
104	Bar-Or et al., <i>Biochem. Biophys. Res. Commun.</i> , 282:356-360 (2001)
105	Bar-Or et al., <i>Free Rad. Biol. Med.</i> , 32(2):197-199 (2002)
106	Bar-Or et al., abstr. P416 in American Peptide Society "Abstract Book" from 17th American Peptide Symposium, San Diego, California, June 2001
107	Bar-Or et al., <i>Biochem. Biophys. Res. Commun.</i> , 290:1388-1392 (2002)
108	Bar-Or et al., text of poster presented at 17th American Peptide Symposium, San Diego, California, June 2001, found at http://www.5z.com/aps/ , 2/19/02
109	Beaulieu et al., <i>J. Cerebral Blood Flow and Metabolism</i> , 18:1022-1031 (1998)
110	Belayev et al., <i>J. Neurotrauma</i> , 16(6):445-453 (1999)
111	Boggs, "Copper chelation suppresses experimental liver tumor growth," found at http://www.huntsmanccancer.org/content/reuters/2001/12/21/200112221scie001.html , January 28, 2002
112	Bossu et al., <i>Inorganic Chemistry</i> , 17(4):1034-1042 (1978)
113	Bourdon et al., <i>FASEB J.</i> , 13:233-244 (1999)
114	Buranaprapuk et al., <i>Biochim Biophys Acta</i> , 1387:309-316 (1998)
115	Calabrese et al., <i>Biochem. J.</i> , 238:291-295 (1986)
116	Canter et al., <i>FEBS</i> , 325(1,2):39-48 (1993)
117	Chakrabarti, <i>Protein Engineering</i> , 4(1):57-63 (1990)
118	Chan et al., <i>Eur. J. Biochem.</i> , 227:524-528 (1995)
119	Cotelle et al., <i>J. Inorganic Biochemistry</i> , 46:7-15 (1992)
120	Das et al., <i>Methods in Enzymology</i> , 233:601-611 (1994)
121	Davies, <i>J. Biol. Chem.</i> , 262(20):9902-9907 (1987)
122	Davies, <i>J. Biol. Chem.</i> , 262(20):9895-9901 (1987)
123	Davies, <i>J. Biol. Chem.</i> , 262(20):9914-9920 (1987)
124	Davies, <i>J. Biol. Chem.</i> , 262(20):9908-9913 (1987)
125	Duchette et al., "Copper Reduction Therapy as an Antiangiogenic Treatment for Lymphoma and other Cancers," found at http://www.coldcure.com/html/anti_ang.htm , 3/5/01, 23 pages

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	


FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	ATTY. DOCKET NO. 4172-3-2	SERIAL NO. 10/076,071
	APPLICANT BAR-OR et al.	
	FILING DATE February 13, 2002	GROUP ART 1614



126	Dunphy et al., <i>Am. J. Physiol.</i> , 276 :H1591-H1598 (1999)
127	Farkas et al., <i>J. Chem. Soc. Dalton Trans.</i> , pp. 611-614 (1984)
128	Florence, <i>Australian and New Zealand J. Opthamol.</i> , 23 (1):3-7 (1995)
129	Fu et al., <i>Biochem. J.</i> , 333 :519-525 (1998)
130	Gutteridge et al., <i>Biochim. Biophys. Acta</i> , 759 :38-41 (1983)
131	Halliwell et al., <i>Arch. Biochem. Biophys.</i> , 246 (2):501-514 (1986)
132	Halliwell et al., "Free Radicals in Biology and Medicine" pp. 1-21 (2nd ed. Clarendon Press - Oxford 1989)
133	Halliwell et al., <i>Arch. Biochem. Biophys.</i> , 280 (1):1-8 (1990)
134	Harford et al., <i>Acc. Chem. Res.</i> , 30 :123-130 (1997)
135	He et al., <i>Biochemistry</i> , 38 :9704-9711 (1999)
136	Hirose et al., <i>Biochim. Biophys. Acta</i> , 1296 :103-111 (1996)
137	Hisatomi et al., <i>Transplantation</i> , 52 (4):754-755 (1991)
138	Huh et al., <i>Brain Res.</i> , 804 :105-113 (1998)
139	Karck et al., <i>J. Heart Lung Transplant</i> , 11 :979-85 (1992)
140	Keller et al., <i>Chem. Res. Toxicol.</i> , 6 :430-433 (1993)
141	Kerr et al., <i>Heart Lung</i> , 25 :200-9 (1996)
142	Khan et al., <i>Biochem. Pharmacol.</i> , 43 (9):1963-1967 (1992)
143	Kimoto et al., <i>Cancer Res.</i> , 43 (2):824-828 (1983) Abstr. in PubMed- PMID: 6293704
144	Knight, <i>Ann. Clin. Lab. Sci.</i> , 25 (2):111-121 (1995)
145	Koch et al., <i>Chemistry & Biology</i> , 4 :549-560 (1997)
146	Kowalik-Jankowska et al., "Copper(II) Complexes with Oligopeptides Containing Serine, Methionine or Phenylalanine Residues" pp. 1184-1197 (9/24/1992)
147	Kowalik-Jankowska et al., <i>J. Inorg. Biochem.</i> , 66 :193-196 (1997)
148	Kruck et al., <i>Can. J. Chem.</i> , 54 :1300-1308 (1976)
149	Lappin et al., <i>Inorganic Chemistry</i> , 17 (6):1630-1634 (1978)
150	Lau et al., <i>Biochem J.</i> , 257 (3) 745-750 (1989) Abstr. in PubMed- PMID: 2467660
151	Laussac et al., <i>Biochemistry</i> , 23 :2832-2838 (1984)
152	Leeuwenburgh et al., <i>Am J. Physiol.</i> , 274 :R453-R461 (1998)
153	Legrand et al., <i>Biochimie</i> , 70 :1185-1195 (1988)
154	Little et al., <i>Neurosurgery</i> , 9 (5):552-558 (1981)
155	Loban et al., <i>Clinical Science</i> , 93 :445-451 (1997)

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	ATTY. DOCKET NO. 4172-3-2	SERIAL NO. 10/076,071
	APPLICANT BAR-OR et al.	
	FILING DATE February 13, 2002	GROUP ART 1614



156	Machonkin et al., <i>Biochemistry</i> , 37:9570-9578 (1998)
157	Malins et al., <i>Proc. Natl. Acad. Sci USA</i> , 93:2557-2565 (1996)
158	Malmström et al., <i>Curr Op. Chem. Biol.</i> , 2:286-292 (1998)
159	Manso, <i>Rev. Port. Cardiol.</i> , 11(11):997-999 (1992)
160	Maret et al., <i>Methods in Enzymology</i> , 226:52-71 (1993)
161	Marx et al., <i>Biochem. J.</i> , 236:397-400 (1985)
162	Masuoka et al., <i>J. Biol. Chem.</i> , 268(29):21533-21537 (1993)
163	McGuirl et al., <i>Curr. Op. Chem. Biol.</i> , 3:138-144 (1999)
164	Miller et al., <i>Arch. Biochem. Biophys.</i> , 295(2):240-246 (1992)
165	Mlynarz et al., "α-Hydroxymethylserine (HMS) Makes HMS-HMS-His the Most Efficient Tripeptide Ligand for Cu ²⁺ Ions" (1998) Speciation 98:Abstract
166	Musci et al., <i>Arch. Biochem. Biophys.</i> , 306(1):111-118 (1993)
167	Odeh, <i>N Eng. J. Med</i> , 324(20):1417-1422 (1991)
168	Praticò et al., <i>J. Clin. Invest.</i> , 100(8):2028-2034 (1997)
169	Predki et al., <i>Biochem. J.</i> , 287:211-215 (1992)
170	Quinlan et al., <i>J. Pharm. Sci.</i> , 81(7):611-614 (1992)
171	Rao et al., <i>Ann. Thorac. Surg.</i> , 52:908-12 (1991)
172	Regan, <i>Annu. Rev. Biophys. Biomol. Struct.</i> , 22:257-81 (1993)
173	Regan, <i>TIBS</i> 20, pp. 280-285 (1995)
174	Remmers et al., <i>Brain Research</i> , 827:237-242 (1999)
175	Rosenthal et al., <i>Free Radical Biology & Medicine</i> , 12:29-33 (1992)
176	Röth, <i>Acta Chirurgica Hungarica</i> , 36(1-4):302-305 (1997)
177	Rupp et al., <i>Biochim. Biophys. Acta.</i> , 446:151-165 (1976)
178	Russell et al., <i>Free Radical Biology & Medicine</i> , 25(2):153-159 (1998)
179	Rylkov et al., <i>Eur. J. Biochem.</i> , 197:185-189 (1991)
180	Sadler et al., <i>Eur. J. Biochem.</i> , 220:193-200 (1994)
181	Salvemini et al., <i>Science</i> , 286:304-306 (1999)
182	Si et al., <i>GLIA</i> , 21:413-418 (1997)
183	Smith et al., <i>J. Histochem. Cytochem.</i> , 46:731-735 (1998)
184	Spencer et al., <i>J. Cardiovasc. Pharmacol.</i> , 32(3):343-348 (1998)
185	Stohs, <i>J. Basic & Clin. Physiol. Pharmacol.</i> , 6(3-4):205-229 (1995)

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	ATTY. DOCKET NO. 4172-3-2	SERIAL NO. 10/076,071
	APPLICANT BAR-OR et al.	
	FILING DATE February 13, 2002	GROUP ART 1614

✓	186	Sutherland et al., abstr. P078 in Abstracts of Communications to be presented at the 10th International Congress on Cardiovascular Pharmacotherapy, Kyoto Japan, March 2001
✓	187	Sutherland et al., <i>J. Cardio. Pharmacol.</i> , 39 :722-728 (200-2)
	188	Süzer et al., <i>Pharmacol. Res.</i> , 37 (2):97-101 (1998)
	189	Ueda et al., <i>Chem. Pharm. Bull.</i> , 43 (2):359-361 (1995)
	190	Ueda et al., <i>Free Radical Biology & Medicine</i> , 18 (5):929-933 (1995)
	191	Ueda et al., <i>J. Inorgan. Biochem.</i> , 55 :123-130 (1994)
	192	Whittall et al., <i>Protein Science</i> , 9 :332-343 (2000)
	193	Wolff et al., <i>TIBS</i> 11 , pp. 27-31 (1986)
	194	Wysocki et al., <i>Coronary Artery Disease</i> , 4 :645-647 (1993)
	195	Yamada et al., <i>Biochem. Mol. Biol. Intl</i> , 46 (4):733-738 (1998)
	V	Yoon et al., <i>J. Surg Res</i> , 46 :163-165 (1989)

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	